Freedom of Information request on the PAR and therapeutic indications for the glycopyrronium products by Morningside Healthcare (FOI 21/1317)
Published 31 May 2022
漏 Crown copyright 2022
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: [email protected].
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at /government/publications/freedom-of-information-responses-from-the-mhra-week-commencing-20-december-2021/freedom-of-information-request-on-the-par-and-therapeutic-indications-for-the-glycopyrronium-products-by-morningside-healthcare-foi-211317
FOI 21/1317
24th December 2021
Dear,
Thank you for your email.
The PAR for the glycopyrronium products by Morningside Healthcare is linked below:
The following PAR is published for the requested therapeutic indications:
Kind regards,
MHRA Customer Service Centre
Medicines and Healthcare products Regulatory Agency
10 South Colonnade, Canary Wharf, London E14 4PU
Telephone 020 3080 6000